Organogenesis Corp - ORGO Enterprise Value to EBITDA Ratio
The EV/EBITDA multiple for capital-intensive businesses reflects the valuation dynamics of Organogenesis Holdings (ORGO), where the value 0.00 characterizes this level. This regenerative medicine leader is valued by physicians for the high efficacy of its biomaterials in treating chronic wounds. The integration of products into surgery has created an indispensable limb-salvage ecosystem. Steady demand is driven by an aging population and the modernization of clinics, positioning the company beyond the constraints of market cycles.
Analytical breakdowns and data insights for company Organogenesis (ORGO)
- market price and analyst price targets:
- issuer market value details:
- business book valuation details:
- debt obligations and liquidity statistics:
Total Debt to Capital Organogenesis Holdings|ORGO - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Organogenesis Holdings Inc.|ORGO - Company Aggregate Debts|Debt to Book Capitalization Ratio Organogenesis Inc.|ORGO - Company Long-Term Indebtedness|Company Short-Term Debt Organogenesis|Quick Ratio organogenesis.com
- business earnings and investment ratios data:
ORGO - Annual Net Income|Projected Future Earnings Organogenesis Holdings|ORGO - Market Cap to Earnings|Future Price to Earnings Organogenesis Inc.|ORGO - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Organogenesis Corp|ORGO - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Organogenesis|ORGO - Net earnings per share for the last four quarters|Quarterly EPS earnings growth organogenesis.com|ORGO - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Organogenesis Holdings
- revenue and sales details:
Fundamental company analysis:ORGO (Organogenesis)
For the long-term investor, the reliability of Organogenesis Holdings (ORGO) is determined by its ability to capitalize R&D in bioengineered matrices while managing its debt load. An analysis of the company's historical EV/EBITDA trends allows for a correlation between the total enterprise value and its operating profit before interest, taxes, depreciation, and amortization, which objectively demonstrates the degree of asset overvaluation and the sustainability of the financial model within the regenerative medicine sector.
Competitor analysis for Organogenesis Holdings
HCA Healthcare - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio THC (Tenet Healthcare Corporation)|Fresenius Medical Care - EV/EBITDA Multiple|Solventum Corp - Enterprise Value to Operating Income Before Depreciation Ratio|Encompass Health (EHC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation UHS|Enterprise Value to EBITDA Ratio DVA|EV/EBITDA Multiple RadNet, Inc.|Enterprise Value to EBITDA Ratio OPCH (Option Care Health)|SGRY (Surgery Partners) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Premier Health PINC|America's Best Contacts & Eyeglasses (EYE) - Company Value to EBITDA|PGNY: Enterprise Value to EBITDA Ratio|ARDT (Ardent Health Partners) - Enterprise Value to Operating Income Before Depreciation|SEM (Select Medical Holdings) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation ASTH|Enterprise Value to EBITDA Ratio MD|USPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization The Pennant Group (PNTG)|NUTX - Company Value to EBITDA|aunainvestors.com - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple SBC Medical Group Holdings Inc. SBC|Evolus Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CYH (Community Health Systems Inc)|SKIN (Beauty Health) - Enterprise Value to EBITDA Ratio|MDWD (MediWound Ltd.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BTMD (biote Corp) - EV/EBITDA Multiple|Company Value to EBITDA The Joint Corp JYNT|EV/EBITDA Multiple DCGO|Enterprise Value to EBITDA Ratio p3hp.org PIII|Gain Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|EUDA: Enterprise Value to Operating Income Before Depreciation|baselmedical.com - EV/EBITDA Multiple|Company Value to EBITDA collplant.com|Cuprina Holdings Limited (CUPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CCM - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization American Shared Hospital Services Inc|Enterprise Value to Operating Income Before Depreciation MRM (MEDIROM Healthcare Group)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avalon GloboCare Corp. (ALBT)|Enterprise Value to EBITDA Ratio DIH Holding US Inc. DHAI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization carmellcosmetics.com XAGE|NIVF - Enterprise Value to EBITDA Ratio|ATIP: Enterprise Value to EBITDA Ratio|CMAX - EV/EBITDA Multiple|KDLY: EV/EBITDA Multiple|Company Value to EBITDA ModivCare (MODV)|NVOS (Novo Integrated Sciences Corp) - EV/EBITDA Multiple|sunlinkhealth.com (SSY) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio BACK (IMAC Regeneration Centers)
